English

CS MEDICA's Subsidiary, CANNORDIC, Signs Distributor Partnership with PHARMALINK

Report this content

Expanding Access to Innovative Healthcare Solutions in the UAE

CS MEDICA A/S, a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD, announces a new distributor partnership between its subsidiary, CANNORDIC, and PHARMALINK, a reliable partner with a strong footprint established over 30 years in the United Arab Emirates (UAE).

This collaboration introduces CANNORDIC's 9 products under the CANNASEN® brand across the UAE market through Pharmalink’s own extensive marketing, distribution and retail network, enhancing healthcare options with innovative cannabinoid-infused products.

PHARMALINK, with a robust team including about 350 marketing and sales representatives, 430+ brands, and 120+ partners, maintains established ties with top Danish and international pharmaceutical entities. This partnership forecasts an order pipeline of 10,000 units per product, valued at EUR 476T.


CANNORDIC is actively working towards obtaining necessary local registrations in the UAE due to a high pull effect from the MENA region. Additionally, the company is executing a two-tier market approach, which includes running a Minimum Viable Product (MVP) program to gather market feedback. This dual strategy ensures that as soon as the registrations are approved, CANNORDIC's products will be adapted and ready for production, facilitating a swift launch in this new market.

Hence, the partnership aims to convert the order pipeline into revenue upon completion of local product registrations and subsequent production launches within 6-8 months, faster than average to date.
 

Dr. Abdul Rauf Jabour, CEO of PHARMALINK, expresses his vision behind the partnership: "At Pharmalink, and through our MEDICINA and Al Manara chain of pharmacies, we strive to pioneer and integrate innovative health solutions that meet the high standards of care we uphold. Choosing CANNORDIC's CANNASEN® brand was a strategic decision driven by our commitment to offer only the best-in-class treatment options. We believe CANNASEN's unique approach to healthcare will benefit our customers, helping them live healthier and happier lives."

Lone Henriksen, CEO of CS MEDICA, commented, "The partnership with PHARMALINK represents a significant milestone for CANNORDIC. Collaborating with a well-established partner like PHARMALINK, who has a profound understanding of the regional healthcare landscape and consumer needs, will enhance our market presence and consumer access to our innovative products."

 


For more information about CS MEDICA, please contact:
Lone Henriksen, CEO
Phone: + (45) 71 20 30 47
Email: lh@cs-medica.com
Website: https://www.cs-medica.com/

 

PHARMALINK operates a network of around 200 pharmacies across the UAE, including its flagship chain, Medicina and Al Manara pharmacies. Based in Abu Dhabi and Dubai, PHARMALINK has established itself as a trusted partner in the pharmaceutical industry, recognized for its strong alliances with Danish and international health brands.
 

CS MEDICA A/S, a Danish MedTech pioneer, specializes in developing evidence-based, CBD-integrated treatments for pain management, autoimmune and stress-related disorders. With a focus on patient-centric care, our products range from innovative R&D to registered over-the-counter substance-based medical devices and dermaceuticals. Our flagship CANNASEN® brand, alongside our own-label solutions, exemplifies our dedication to safe, high-quality treatments for both human and veterinary health globally. The company is listed on Spotlight Stock Market in Stockholm (symbol: “CSMED”). For more information, visit cs-medica.com and LinkedIn.

CANNORDIC A/S, a subsidiary of CS MEDICA Group, is a pioneering MedTech company specializing in innovative substance-based medical devices containing bioactive CBD. Our dedication to enhancing lives by integrating innovation, science, technology, and natural cannabis compounds positions it as a pioneer in the medical technology industry. The company ensures robust research, development, manufacturing, compliance, data insights, and commercialization processes. 
 

Tags:

OTC UAE Compliance distribution agreement pharma mena CBD market expansion CANNASEN

Subscribe

Documents & Links

Quick facts

This collaboration introduces CANNORDIC's 9 products under the CANNASEN® brand across the UAE market through Pharmalink’s own extensive marketing, distribution and retail network, enhancing healthcare options with innovative cannabinoid-infused products.
Tweet this
PHARMALINK, with a robust team including about 350 marketing and sales representatives, 430+ brands, and 120+ partners, maintains established ties with top Danish and international pharmaceutical entities. This partnership forecasts an order pipeline of 10,000 units per product, valued at EUR 476T.
Tweet this
The partnership aims to convert the order pipeline into revenue upon completion of local product registrations and subsequent production launches within 6-8 months, faster than average to date.
Tweet this

Quotes

At Pharmalink, and through our MEDICINA and Al Manara chain of pharmacies, we strive to pioneer and integrate innovative health solutions that meet the high standards of care we uphold. Choosing CANNORDIC's CANNASEN® brand was a strategic decision driven by our commitment to offer only the best-in-class treatment options. We believe CANNASEN's unique approach to healthcare will benefit our customers, helping them live healthier and happier lives.
Dr. Abdul Rauf Jabour, CEO of PHARMALINK
The partnership with PHARMALINK represents a significant milestone for CANNORDIC. Collaborating with a well-established partner like PHARMALINK, who has a profound understanding of the regional healthcare landscape and consumer needs, will enhance our market presence and consumer access to our innovative products.
Lone Henriksen, CEO of CS MEDICA